nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—Henoch-Schonlein purpura—Hydrochlorothiazide—nephrolithiasis	0.045	0.048	CcSEcCtD
Sibutramine—Hair disorder—Hydrochlorothiazide—nephrolithiasis	0.045	0.048	CcSEcCtD
Sibutramine—Abnormal faeces—Hydrochlorothiazide—nephrolithiasis	0.0357	0.0381	CcSEcCtD
Sibutramine—Intraocular pressure increased—Hydrochlorothiazide—nephrolithiasis	0.0232	0.0248	CcSEcCtD
Sibutramine—Anorectal disorder—Hydrochlorothiazide—nephrolithiasis	0.0194	0.0207	CcSEcCtD
Sibutramine—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.0151	0.0161	CcSEcCtD
Sibutramine—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.0142	0.0151	CcSEcCtD
Sibutramine—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0133	0.0142	CcSEcCtD
Sibutramine—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.0133	0.0142	CcSEcCtD
Sibutramine—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0124	0.0132	CcSEcCtD
Sibutramine—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.011	0.0117	CcSEcCtD
Sibutramine—Gout—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0117	CcSEcCtD
Sibutramine—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0115	CcSEcCtD
Sibutramine—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.0107	0.0114	CcSEcCtD
Sibutramine—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0111	CcSEcCtD
Sibutramine—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0109	CcSEcCtD
Sibutramine—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.01	0.0107	CcSEcCtD
Sibutramine—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.00964	0.0103	CcSEcCtD
Sibutramine—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00933	0.00995	CcSEcCtD
Sibutramine—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00923	0.00984	CcSEcCtD
Sibutramine—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00856	0.00913	CcSEcCtD
Sibutramine—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00852	0.00909	CcSEcCtD
Sibutramine—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.00844	0.009	CcSEcCtD
Sibutramine—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00836	0.00892	CcSEcCtD
Sibutramine—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00829	0.00883	CcSEcCtD
Sibutramine—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00814	0.00868	CcSEcCtD
Sibutramine—Injury—Hydrochlorothiazide—nephrolithiasis	0.00807	0.0086	CcSEcCtD
Sibutramine—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00799	0.00852	CcSEcCtD
Sibutramine—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00789	0.00841	CcSEcCtD
Sibutramine—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00782	0.00834	CcSEcCtD
Sibutramine—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00779	0.0083	CcSEcCtD
Sibutramine—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00779	0.0083	CcSEcCtD
Sibutramine—Purpura—Hydrochlorothiazide—nephrolithiasis	0.00769	0.0082	CcSEcCtD
Sibutramine—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00763	0.00813	CcSEcCtD
Sibutramine—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00741	0.0079	CcSEcCtD
Sibutramine—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00741	0.0079	CcSEcCtD
Sibutramine—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00735	0.00784	CcSEcCtD
Sibutramine—Migraine—Hydrochlorothiazide—nephrolithiasis	0.0073	0.00778	CcSEcCtD
Sibutramine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0073	0.00778	CcSEcCtD
Sibutramine—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00716	0.00763	CcSEcCtD
Sibutramine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00702	0.00749	CcSEcCtD
Sibutramine—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00697	0.00743	CcSEcCtD
Sibutramine—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00695	0.0074	CcSEcCtD
Sibutramine—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00684	0.0073	CcSEcCtD
Sibutramine—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.0068	0.00724	CcSEcCtD
Sibutramine—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00677	0.00722	CcSEcCtD
Sibutramine—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00675	0.00719	CcSEcCtD
Sibutramine—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00668	0.00712	CcSEcCtD
Sibutramine—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00656	0.00699	CcSEcCtD
Sibutramine—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00654	0.00697	CcSEcCtD
Sibutramine—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00654	0.00697	CcSEcCtD
Sibutramine—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00645	0.00688	CcSEcCtD
Sibutramine—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00641	0.00683	CcSEcCtD
Sibutramine—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00641	0.00683	CcSEcCtD
Sibutramine—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00624	0.00665	CcSEcCtD
Sibutramine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00599	0.00639	CcSEcCtD
Sibutramine—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00592	0.00631	CcSEcCtD
Sibutramine—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0059	0.00629	CcSEcCtD
Sibutramine—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00585	0.00624	CcSEcCtD
Sibutramine—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00583	0.00622	CcSEcCtD
Sibutramine—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00578	0.00616	CcSEcCtD
Sibutramine—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00575	0.00613	CcSEcCtD
Sibutramine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00563	0.006	CcSEcCtD
Sibutramine—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00562	0.00599	CcSEcCtD
Sibutramine—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.0056	0.00597	CcSEcCtD
Sibutramine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.0056	0.00597	CcSEcCtD
Sibutramine—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00555	0.00592	CcSEcCtD
Sibutramine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00555	0.00592	CcSEcCtD
Sibutramine—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00548	0.00584	CcSEcCtD
Sibutramine—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00545	0.00581	CcSEcCtD
Sibutramine—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00539	0.00574	CcSEcCtD
Sibutramine—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00536	0.00571	CcSEcCtD
Sibutramine—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00522	0.00557	CcSEcCtD
Sibutramine—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00514	0.00548	CcSEcCtD
Sibutramine—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.0051	0.00544	CcSEcCtD
Sibutramine—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00509	0.00543	CcSEcCtD
Sibutramine—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00505	0.00539	CcSEcCtD
Sibutramine—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00494	0.00527	CcSEcCtD
Sibutramine—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00478	0.0051	CcSEcCtD
Sibutramine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00458	0.00488	CcSEcCtD
Sibutramine—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00453	0.00483	CcSEcCtD
Sibutramine—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.0044	0.00469	CcSEcCtD
Sibutramine—Tension—Hydrochlorothiazide—nephrolithiasis	0.00438	0.00467	CcSEcCtD
Sibutramine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00437	0.00466	CcSEcCtD
Sibutramine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00434	0.00462	CcSEcCtD
Sibutramine—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00432	0.0046	CcSEcCtD
Sibutramine—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00429	0.00458	CcSEcCtD
Sibutramine—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00421	0.00449	CcSEcCtD
Sibutramine—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00418	0.00446	CcSEcCtD
Sibutramine—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00414	0.00442	CcSEcCtD
Sibutramine—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00413	0.0044	CcSEcCtD
Sibutramine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.0041	0.00437	CcSEcCtD
Sibutramine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00408	0.00435	CcSEcCtD
Sibutramine—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00403	0.00429	CcSEcCtD
Sibutramine—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00401	0.00428	CcSEcCtD
Sibutramine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.004	0.00427	CcSEcCtD
Sibutramine—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.004	0.00426	CcSEcCtD
Sibutramine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00395	0.00421	CcSEcCtD
Sibutramine—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00392	0.00418	CcSEcCtD
Sibutramine—Cough—Hydrochlorothiazide—nephrolithiasis	0.0039	0.00415	CcSEcCtD
Sibutramine—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.0038	0.00405	CcSEcCtD
Sibutramine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.0038	0.00405	CcSEcCtD
Sibutramine—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.0038	0.00405	CcSEcCtD
Sibutramine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00379	0.00404	CcSEcCtD
Sibutramine—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00376	0.004	CcSEcCtD
Sibutramine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00372	0.00396	CcSEcCtD
Sibutramine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00367	0.00392	CcSEcCtD
Sibutramine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00364	0.00388	CcSEcCtD
Sibutramine—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00364	0.00388	CcSEcCtD
Sibutramine—Shock—Hydrochlorothiazide—nephrolithiasis	0.00358	0.00382	CcSEcCtD
Sibutramine—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00357	0.0038	CcSEcCtD
Sibutramine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00356	0.00379	CcSEcCtD
Sibutramine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00352	0.00376	CcSEcCtD
Sibutramine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00347	0.0037	CcSEcCtD
Sibutramine—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.0034	0.00363	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00332	0.00354	CcSEcCtD
Sibutramine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.0033	0.00351	CcSEcCtD
Sibutramine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00349	CcSEcCtD
Sibutramine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00346	CcSEcCtD
Sibutramine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00324	0.00345	CcSEcCtD
Sibutramine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00321	0.00342	CcSEcCtD
Sibutramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.0032	0.0516	CbGpPWpGaD
Sibutramine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00317	0.00338	CcSEcCtD
Sibutramine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00312	0.00332	CcSEcCtD
Sibutramine—Pain—Hydrochlorothiazide—nephrolithiasis	0.00312	0.00332	CcSEcCtD
Sibutramine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.003	0.0032	CcSEcCtD
Sibutramine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00298	0.00318	CcSEcCtD
Sibutramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00297	0.0479	CbGpPWpGaD
Sibutramine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00289	0.00309	CcSEcCtD
Sibutramine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00288	0.00307	CcSEcCtD
Sibutramine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00288	0.00307	CcSEcCtD
Sibutramine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00283	0.0457	CbGpPWpGaD
Sibutramine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00268	0.00286	CcSEcCtD
Sibutramine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00263	0.0425	CbGpPWpGaD
Sibutramine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00279	CcSEcCtD
Sibutramine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00258	0.00275	CcSEcCtD
Sibutramine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00249	0.00266	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.00249	0.0402	CbGpPWpGaD
Sibutramine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00241	0.00257	CcSEcCtD
Sibutramine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00232	0.00247	CcSEcCtD
Sibutramine—Rash—Hydrochlorothiazide—nephrolithiasis	0.0023	0.00245	CcSEcCtD
Sibutramine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.0023	0.00245	CcSEcCtD
Sibutramine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00228	0.00243	CcSEcCtD
Sibutramine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00216	0.00231	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00214	0.0346	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.0021	0.0338	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00192	0.0309	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00192	0.0309	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SLC2A9—nephrolithiasis	0.0019	0.0306	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00186	0.0299	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0017	0.0274	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0017	0.0274	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00145	0.0234	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00145	0.0234	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00135	0.0218	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00135	0.0218	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00129	0.0208	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00129	0.0208	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.0012	0.0194	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0012	0.0193	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0012	0.0193	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00119	0.0193	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00119	0.0193	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00107	0.0172	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00106	0.0172	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00106	0.0171	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00106	0.0171	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000974	0.0157	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000974	0.0157	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000943	0.0152	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000863	0.0139	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000863	0.0139	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000738	0.0119	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000738	0.0119	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000686	0.0111	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000686	0.0111	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000654	0.0105	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000654	0.0105	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000612	0.00986	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000612	0.00986	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000608	0.0098	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000608	0.0098	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000542	0.00874	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000542	0.00874	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.00051	0.00822	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000489	0.00789	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000433	0.00699	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000115	0.00186	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000103	0.00165	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—APRT—nephrolithiasis	8.72e-05	0.00141	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	8.72e-05	0.00141	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AQP1—nephrolithiasis	6.21e-05	0.001	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CHRM3—nephrolithiasis	5.62e-05	0.000906	CbGpPWpGaD
